Press ReleasesLatest news from MBio
MBio Diagnostics Announces a License and Development Partnership with Heska for the Veterinary Market
New collaboration to deliver on-the-spot, rapid, multiplex testing solutions with laboratory quality performance directly in the veterinary clinic
May 15, 2018 Boulder, CO – MBio Diagnostics, Inc., a company leading a new era in rapid, on- the-spot clinical diagnostics and sample testing, today announced a product development partnership and licensing agreement with Heska Corporation (Nasdaq: HSKA), a veterinary diagnostics company focused on providing advanced testing solutions for the animal health market. This is an exclusive partnership for multiplex immunoassay tests utilizing MBio’s LightDeck® platform. MBio Diagnostics and Heska will jointly carry out product development to capitalize on the strengths of both companies.
The MBio Array System utilizes MBio’s proprietary LightDeck® technology, enabling simple, multiplex testing in a compact system. When paired with Heska’s proprietary reagents, the MBio system enables multiplexed, high sensitivity assays directly in the vet clinic without needing to send out to an expensive reference laboratory. MBio’s immunoassay system enables tests for diverse applications such as vector-borne diseases, parasitology, and animal heath and wellness. This portable, easy-to-use multiplex reader can be placed into a wide variety of testing situations, from clinics to animal hospital labs, taking only little space.
According to MBio CEO Chris Myatt; “Commercialization partnerships are an important aspect of MBio’s business strategy. We have made enormous progress advancing our platform technology in recent years, and we are now executing on strategic partnerships that open new high-value opportunities.” Dr. Myatt added, “Recent developments in the veterinary field have emphasized the value of multiplex testing solutions. Our partnership with Heska will provide this high quality of testing directly in the clinic.”
Commenting on the development, Heska CEO Kevin Wilson noted, “We are excited to partner with a US based, local technology company for our leading edge, high sensitivity, multiplex testing solutions. MBio’s fantastic innovation, when combined with Heska’s experience providing gold standard healthcare solutions to the veterinary field, will provide veterinarians and their patients accurate, reliable, best in class results and as we build out the test menu, entirely new classes of point of care testing.”
About MBio Diagnostics
MBio Diagnostics provides rapid, on-the-spot testing solutions for our global commercial partners. Our portable LightDeck® platform delivers panels of lab-quality results in minutes for critical applications in health care, veterinary, and environmental industries.
About LightDeck® Technology
MBio’s patented LightDeck® technology system translates laboratory assays into on-the-spot, critical decisions in minutes. Our LightDeck® platform incorporates low-cost, multiplexed cartridges with our fluorescent readers and intuitive software, with the ability to measure more than 50 analytes in a single cartridge. Our partners use LightDeck® technology to test key analytes across many applications for competitive advantages in the areas of quantitative sensitivity, multiplexing, and speed.
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and specialty products. Heska’s state-of-the-art offerings include point of care laboratory instruments and supplies, digital imaging products, software and services, vaccines, local and cloud-based data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company’s core focus is on supporting veterinarians in the canine and feline healthcare space. For further information on Heska and its products, visit www.heska.com.
Chief Marketing Officer
267-496-6391 ● Carrie.Mulherin@MBioDx.com